How have you incorporated donor-derived cell-free DNA to help with the diagnosis of rejection or monitoring of the treatment response to rejection?  

I typically use it in lieu of an allograft biopsy in patients on surveillance, particularly if there are reasons to avoid a biopsy (antiplatelet agents, bleeding risk, difficult anatomy). Serial cf-DNA levels that improve following treatment of rejection have been helpful as well to give us an idea ...